Proteocyte Welcomes Key Advisor Mark Smithyes as Strategic Advisor

Toronto, ON; November 3, 2023 – Proteocyte AI is pleased to announce that Mark Smithyes has joined the organization as a strategic advisor. Mark will play a key role in helping Proteocyte to raise additional capital as the company approaches several key milestones for broader commercialization in Canada and the United States. He brings over 25 years of senior-level experience at multinational life science companies like Novartis and Alcon, as well as experience in building start-ups. Mark is the past Chair of the Board of Life Sciences Ontario, with considerable prior involvement in life sciences and healthcare as well – both in a corporate capacity and as an advocate. John Jordan, Chief Financial Officer at Proteocyte: “Mark’s arrival as a strategic advisor adds another layer of financial robustness as we continue to roll out STRATICYTE™, our oral cancer risk assessment product. He provides yet another boost to Proteocyte’s growing roster of top talent.”

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.